KEYNOTE-756
KEYNOTE-756: Phase III Trial of Neoadjuvant Pembrolizumab vs Placebo Plus CT Followed by Adjuvant Pembrolizumab vs Placebo Plus ET in High-Risk, ER+/HER2- EBC

Released: December 07, 2023

Activity

Progress
1
Course Completed